FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to peptide immunosuppressors, and can be used in medicine. Disclosed are polypeptides based on TREM-like transcript 1 (TLT-1), as well as conjugates and proteins fused with them.
EFFECT: invention provides upregulation of PD-L1 expression and down regulation of HLA-DR expression by binding the disclosed polypeptides directly to immune cells and inducing immunosuppressive phenotypes, which can be useful for treating diseases associated with immune hyperreactivity, such as autoimmune diseases, hypersensitivity reactions, transplant rejection and graft versus host reaction.
13 cl, 4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW POLYPEPTIDE WITH AFFINITY FOR PD-L1 | 2016 |
|
RU2749110C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
